Deutsche Bank initiated coverage of Denali Therapeutics (DNLI) with a Buy rating and $31 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics announces primary analysis of Phase 1/2 study in MPS II
- Denali Therapeutics Outlines 2025 Milestones and Strategies
- Denali Therapeutics announces U.S. FDA BTD granted for tividenofusp
- Denali recent pullback a buying opportunity, says Jefferies
- BofA trims Denali Therapeutics price target to $30, says weakness an opportunity